The present invention discloses an enteric citalopram pellet comprising a) a core consisting of citalopram and one or more pharmaceutically acceptable excipients; b) an optional separating layer; c) an enteric layer comprising hydroxypropyl-methylcellulose acetate succinate (HPMCAS) and a pharmaceutically acceptable...

The present invention provides effective injectable formulation of diclofenac that produces minimal or no pain or burning sensation upon administration.

The present invention provides the small oral dosage form of Losartan or its pharmaceutically acceptable salt. Optionally in combination with hydrochlorothiazide (HCTZ).

A pharmaceutical preparation suitable for oral administration is disclosed. The composition comprises; a core; and a coating which comprises an effective amount of fluconazole; an emulsifier; a binder; and a solid phase acid; wherein the solid phase acid is selected from atleast one of maleic acid, succininc acid, m...

The present invention relates to a pharmaceutical composition for oral administration and in particular to an enteric coated composition of Topiramate in the form of coated tablets

The present invention relates to a pharmaceutical composition for oral administration and in particular to an enteric coated composition of Pantoprazole in the form of coated tablets.

Novel pharmaceutical dosage forms which provides for therapeutic amount of a pharmaceutically acceptable salt of Amiodarone that releases the drug in spaced apart "pulses."

This present invention relates to a stable pharmaceutical dosage form including Lansoprazole active ingredient or pharmaceutical acceptable salt.

This present invention relates to a stable pharmaceutical dosage form including Lansoprazole active ingredient or pharmaceutical acceptable salt

The present invention relates to a pharmaceutical composition for oral administration and in particular to an enteric coated composition of duloxetine in the form of coated granules and/or pellets.

This invention relates to a sustained release oral pharmaceutical dosage form containing an effective amount of tramadol, or a pharmaceutically acceptable salt thereof, dispersed in a matrix characterized in that the matrix comprises corn starch.

Novel pharmaceutical dosage forms providing for therapeutic amount of a pharmaceutically acceptable salt of Amiodarone are disclosed. The Amiodarone tablet is provided in a pharmaceutically acceptable polymer matrix comprising at least one continuous polydextrose phase and at least one continuous phase of a polymer ...

An improved Sustained release formulation of Metolazone The present invention provides the new sustained release formulation of metolazone where metolazone itself acts as its own binder to enable the desired high drug loading to be achieved. We postulate that a small proportion of the metolazone dissolves during th...

The present invention provides for a method of delivering Gemcitabinel, the method comprising an intratumoral dose of a Gemcitabinel formulation and an intravenous infusion of Gemcitabinel wherein the intravenous infusion occurs about 24 hours to about 7 days after the intratumoral dose

The present invention relates to capsules of Loratadine including at least one hydrophobic inner core layer and at least one hydrophilic outer layer. Such capsules experience minimal or no degradation under accelerated stability conditions. 22 JUL 2008 12

The present invention discloses novel dispersible tablet comprising (i) of Loratadine and (ii) at least one excipient, which reduces the sedimentation rate of the pharmacologically active ingredient. 22 JUL 2008

The present invention relates to a pharmaceutical composition for oral administration and in particular to an enteric coated composition of Duloxetine in the form of coated tablets.

The invention relates to a coated formulation of Metformin. The invention also relates to a method of making the said solid dosage form. 13

The present invention relates to a pharmaceutical composition for oral administration and in particular to an enteric coated composition of fluoxetine in the form of coated granules and/or pellets.

The present invention relates to pharmaceutical dosage forms of Amlodipine besylate and processes for their preparation.